ASCO GUIDELINES Bundle

Non-Small Cell Lung Cancer Adjuvant Therapy for Completely Resected Stages I–IIIA

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/1475486

Contents of this Issue

Navigation

Page 1 of 3

Key Points ➤ Lung cancers are the leading cause of cancer-related deaths for men and women throughout the world. In the United States, approximately 237,000 new cases of lung cancer are expected in 2022, and more than 130,000 individuals are expected to die as a result of the disease. a ➤ Five-year survival rates range from 67% for T1N0 disease to 23% for patients with in T1-3N2 disease. ➤ Adenocarcinomas and squamous cell lung cancers, which are the focus of this guideline, comprise approximately 82% of all lung cancers. b a American Cancer Society: Key Statistics for Lung Cancer 2022. https://www.cancer.org/ cancer/lung-cancer/about/key-statistics.html b American Cancer Society: Cancer Facts and Figures, 2022. Atlanta, GA, American Cancer Society, 2022. Recommendation Grading Type Benefit/harm Evidence Quality Strength of Recommendation EB Evidence-based B Benefits outweigh harms H High Strong CB/ FC Consensus- based/Panel Consensus H Harms outweigh benefits M Moderate Moderate IC Informal consensus B/H Relative balance of benefits and harms I Intermediate Weak N No recommendation U Benefits/ harms ratio uncertain Ins Insufficient

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Non-Small Cell Lung Cancer Adjuvant Therapy for Completely Resected Stages I–IIIA